Tysabri review reveals no new brain disease cases

10/18/2005 | Yahoo!

Biogen and Elan's review of Tysabri -- the Crohn's disease and rheumatoid arthritis drug once approved for multiple sclerosis -- found no new instances of progressive multifocal leukoencephalopathy among MS patients or patients taking the drug for Crohn's disease and rheumatoid arthritis. The companies pulled the drug from the market on Feb. 28 after it was linked with the rare brain disease but filed to reinstate the drug as an MS treatment on Sept. 26.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC